Massive NIH–industry project opens portals to target validation
Elie Dolgin • February 27, 2019
Five years in, the US$360 million Accelerating Medicines Partnership is yielding tools to speed up drug discovery for rheumatoid arthritis, lupus, diabetes, Alzheimer disease and Parkinson disease.
Continue reading at Nature Reviews Drug Discovery.
With organoids, assembloids and a growing bioengineering toolkit, scientists are pushing the limits of human brain models.
Drug makers are scrambling to navigate an ‘existential threat’ to a once-celebrated technology.